When Headlines Get It Wrong: A Closer Look at a Study on Complementary Medicine and Breast Cancer Survival

A recent study published in JAMA on March 2, 2026 has been circulating through the media with a headline suggesting that the use of complementary and alternative medicine (CAM) in breast cancer is associated with worse survival. Headlines like this can cause significant concern for patients and families who are exploring ways to support their health during cancer treatment. However, when we look more carefully at how the study was designed, several concerns emerge that make the conclusions significantly less straightforward than the headline suggests, which is incredibly frustrating for healthcare providers like myself that practice in this field of health.

The Groups Being Compared Were Not the Same

Let me clarify what I mean by this ... the of the most important issue in this study is the age difference between the groups being analyzed.

Patients who used complementary approaches alongside conventional treatment had a median age of 54, while those receiving conventional treatment alone had a median age of 62. Patients who received no treatment had a median age of 67.

The middle 50% of the patients for the combination group (CAM + conventional care) is 44-63 years, which means 25% of them were under 44 years old! 

This point is significant, and in my opinion invalidates the results of this entire study. In breast cancer, age is closely linked with tumour biology. Younger women are more likely to develop aggressive tumour subtypes, including triple-negative breast cancer (TNBC), HER2-positive disease, elevated Ki-67, indicating faster tumour growth and higher grade/stage at diagnosis due to lack of screening provided to women under 40.

These biological differences are important because they directly influence prognosis.

The statistical models used in the study did not adjust for tumour characteristics such as grade of tumour, ER, PR, or HER2 receptor status. Without accounting for these characteristics, it becomes impossible to determine whether survival differences are related to treatment choices or to underlying tumour biology.

If we go even further into the poor methodology of this study...

Small Subgroups Can Produce Misleading Statistics

The extremely small number of patients categorized as CAM users is another challenge.

The study identified:

• 273 patients in the CAM-only group

• 568 patients using both CAM and conventional therapy

Together, these groups represented less than 0.04% of the total study population. How can you pull conclusions from such a small portion of the study population? That shouldn't even be allowed.

When comparisons are made using groups this small, the smallest of differences in disease characteristics, such as a higher proportion of aggressive tumours, can produce large shifts in risk, which can generate a hazard ratio that appears meaningful.

How Complementary Medicine Was Defined

Another important limitation relates to how the study classified complementary medicine use.

In this research, CAM was defined specifically as treatments delivered by non-medical personnel. As a medical personnel who uses CAM in my practice, this is frustrating.

This narrow definition introduces a major source of potential misclassification.

We know from other studies that 20–30% of breast cancer patients report using some form of integrative therapy, including nutritional strategies, targeted supplementation, acupuncture, physical activity programs, and mind-body approaches. This is very different to the 0.04% found in this March 2026 study. Where are the other 29.96% of people?

Many patients pursue these strategies alongside conventional oncology treatment, often under the supervision of licensed healthcare providers such as physicians, naturopathic doctors, or integrative oncology practitioners.

Because the study only identified CAM use when it was delivered by non-medical providers, it likely failed to capture a large proportion of patients using integrative therapies safely and appropriately because those patients were likely categorized within the “conventional treatment” group, rather than the CAM group.

This type of misclassification can artificially inflate the perceived risk associated with the “CAM” label.

To draw a better conclusion, the researchers should have had a 4th category "CAM delivered by qualified regulated health care providers delivered alongside the full/recommended conventional treatment".

Observational Studies Cannot Establish Cause

Another important reason to read the actual study is to learn about the type of study that was performed. This is an observational study. Observational research examines patterns within existing data sets, but it cannot determine cause and effect. A randomized controlled trial randomly assigns participants to different interventions or control groups, allowing researchers to more reliably determine whether a specific treatment directly causes a particular outcome. We have lots of RCTs that use supplements, dietary modifications, etc with conventional care, and many of them show benefit.

What This Means for Patients

For patients navigating breast cancer treatment, the key takeaway is not that complementary approaches are harmful.

Instead, the evidence continues to support the importance of coordinated care between conventional oncology and qualified integrative regualted healthcare providers, like Naturopathic Doctors.

When implemented thoughtfully and under professional supervision, these approaches aim to support the whole patient while ensuring that conventional treatments remain central to care.

The Bottom Line

Scientific research plays an essential role in improving cancer care. However, the conclusions of any study must be evaluated within the context of its design and limitations. This study has many, do not be fooled by the media headlines. If your oncologist discusses this study with you, please point out the above information.

For patients and clinicians alike, the most important approach remains informed decision-making guided by experienced healthcare professionals who understand both conventional oncology and evidence-informed integrative care.

• Dr. Brenda Tapp Leonard, ND